Excellent Brain Ltd. Announces Joint Venture with MasNeuros to Launch Spanish Neurofeedback Trainers Course
Excellent Brain Ltd. Expands Global Reach with Spanish Neurofeedback Course
Natanya, Israel , June 18, 2025 (GLOBE NEWSWIRE) -- Excellent Brain Ltd., an innovative Israeli start-up renowned for its advanced neurofeedback solutions, has announced a strategic joint venture with MasNeuros, a leading Spanish organization. This collaboration aims to deliver the Excellent Brain's Trainers Course in Spanish, focusing on Neurofeedback for ADHD, utilizing the cutting-edge Excellent Brain Neurofeedback platform.Excellent Brain - Neurofeedback for ADHDThe first course, successfully completed in May 2025, marks a significant milestone in making neurofeedback training accessible to Spanish-speaking clinics. This initiative is set to empower healthcare professionals across Spanish-speaking countries, providing them with the most effective tools for managing ADHD in clinical settings.
Ofer A. Lidsky, CEO and founder of Excellent Brain Ltd., expressed his enthusiasm for the collaboration, stating,
"Partnering with MasNeuros allows us to extend our innovative neurofeedback training to a broader audience. This joint venture is a testament to our commitment to enhancing cognitive health and providing accessible solutions for ADHD management worldwide."
The Excellent Brain Neurofeedback platform is celebrated for its ability to leverage EEG signal processing to enhance brain function. By offering training programs that improve various cognitive aspects, particularly for individuals with ADHD, the platform stands as a beacon of innovation in mental wellness and cognitive enhancement.
This joint venture not only broadens the reach of Excellent Brain's pioneering technology but also reinforces its position as a leader in the field of neurofeedback. By collaborating with MasNeuros, Excellent Brain Ltd. is poised to make a significant impact on the mental health landscape in Spanish-speaking regions.
The completion of the first course signifies the beginning of a new era in neurofeedback training, where language is no longer a barrier to accessing world-class cognitive enhancement tools. Clinics in Spanish-speaking countries can now integrate these advanced solutions into their practices, offering patients the benefits of cutting-edge ADHD management techniques.Brain Training for improving ADHD symptomsAbout Excellent Brain Ltd. Excellent Brain Ltd., founded in 2015 by entrepreneur Ofer A. Lidsky, is an innovative Israeli start-up specializing in advanced neurofeedback solutions. The company's cutting-edge platform leverages EEG signal processing to enhance brain function, offering accessible training programs aimed at improving various cognitive aspects, particularly for individuals with ADHD. Excellent Brain's technology enables users to engage in neurofeedback and virtual reality-based training, promoting mental wellness and cognitive enhancement.
Press inquiries
Excellent Brain Ltd. https://excellent-brain.com Ofer Lidsky ofer@excellent-brain.com
A video accompanying this announcement is available at https://www.youtube.com/embed/34QVOxANqOsSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
an hour ago
- Washington Post
The Latest: Dozens wounded in Iranian strikes across Israel, as Israel hits Arak reactor site
An Iranian missile hit the main hospital in southern Israel early Thursday, wounding people and causing 'extensive damage,' the medical facility said. Israeli media aired footage of blown-out windows and heavy black smoke. Separate Iranian strikes hit a high-rise apartment building in Tel Aviv and other sites in central Israel. At least 40 people were wounded, according to Israel's Magen David Adom rescue service.
CBS News
an hour ago
- CBS News
Israeli hospital hit by Iranian missile as Israel attacks heavy water reactor in Iran
What to expect as Trump weighs whether to enter Israel-Iran conflict Dubai, United Arab Emirates — Israel's main southern hospital sustained a direct hit Thursday from an Iranian missile, with officials reporting "extensive damage." Separate Iranian strikes hit a high-rise apartment building in Tel Aviv and other sites in central Israel. A hospital in Tel Aviv said it had received 16 wounded people, three with serious injuries. The developments came as President Trump was mulling whether the United States would directly take part in Israel's efforts to destroy Iran's nuclear program. A spokesperson for the Soroka Medical Center in Beer Sheba said the hospital suffered "extensive damage" in different areas and people had been wounded in the attack. The hospital has requested that people don't come for treatment. Israeli officials said the part of the hospital that took a direct hit had been evacuated before the strike. The director general of Magen David Adom — Israel's emergency rescue service — said, "Last night, the Ministry of Health gave instructions to further clear the floor that was damaged in Soroka. Many lives were saved." Smoke rises from Soroka Medical Center in Be'er Sheva, Israel following a missile strike from Iran on June 19, 2025. Amir Cohen / REUTERS Israeli Health Minister Uriel Bosso called the attack "an act of terrorism and a crossing of a red line. A war crime by the Iranian regime that was deliberately committed against innocent civilians and medical teams dedicated to saving lives. The Ministry of Health was prepared in advance, and thanks to the immediate actions we took, a very serious disaster was averted." The hospital has over 1,000 beds and provides services to the approximately 1 million residents of southern Israel, according to its website. The strike came as Israel attacked Iran's Arak heavy water reactor, Iranian state television said Thursday. The report said there was "no radiation danger whatsoever." An Iranian state television reporter, appearing live in the nearby town of Khondab, said the facility had been evacuated and there was no damage to civilian areas around the reactor. Israel had warned earlier Thursday morning it would attack the facility and urged the public to flee the area. The Israeli military said Thursday's round of airstrikes targeted Tehran and other areas of Iran, without elaborating. It later said Iran fired a new salvo of missiles at Israel and told the public to take shelter. Israel's seventh day of airstrikes on Iran came a day after Iran's supreme leader rejected U.S. calls for surrender and warned that any military involvement by the Americans would cause "irreparable damage to them." Israel also lifted some restrictions on daily life, suggesting the missile threat from Iran on its territory was easing. Already, Israel's campaign has targeted Iran's uranium enrichment site at Natanz, centrifuge workshops around Tehran and a nuclear site in Isfahan. Its strikes have also killed top generals and nuclear scientists. A Washington-based Iranian human rights group said at least 639 people, including 263 civilians, have been killed in Iran and more than 1,300 wounded. In retaliation, Iran has fired some 400 missiles and hundreds of drones, killing at least 24 people in Israel and wounding hundreds. Some have hit apartment buildings in central Israel, causing heavy damage. The Arak heavy water reactor is 155 miles southwest of Tehran. Heavy water helps cool nuclear reactors, but it produces plutonium as a byproduct that can potentially be used in nuclear weapons. That would provide Iran another path to the bomb beyond enriched uranium, should it choose to pursue the weapon. Iran had agreed under its 2015 nuclear deal with world powers to redesign the facility to relieve proliferation concerns. In 2019, Iran started up the heavy water reactor's secondary circuit, which at the time didn't violate Tehran's 2015 nuclear deal with world powers. Britain at the time was helping Iran redesign the Arak reactor to limit the amount of plutonium it produces, stepping in for the U.S., which had withdrawn from the project after President Trump's decision in 2018 to unilaterally pull America out of the nuclear deal. The International Atomic Energy Agency, the United Nations' nuclear watchdog, has been urging Israel not to strike Iranian nuclear sites. IAEA inspectors reportedly last visited Arak on May 14. Due to restrictions Iran imposed on inspectors, the IAEA has said it has lost "continuity of knowledge" about Iran's heavy water production -- meaning it couldn't absolutely verify Tehran's production and stockpile. As part of negotiations around the 2015 deal, Iran agreed to sell off its heavy water to the West to remain in compliance with the accord's terms. Even the U.S. purchased some 32 tons of heavy water for over $8 million in one deal. That was one issue that drew criticism from the pact's opponents.
Los Angeles Times
9 hours ago
- Los Angeles Times
Tourette Syndrome: A Look at Today's Best Treatments
Tourette syndrome (TS) is more than just a childhood phase of twitching or making sounds—it's a chronic neurodevelopmental condition that can disrupt daily functioning and emotional well-being. Characterized by both motor and vocal tics that begin before age 18 and last for more than a year, Tourette's often brings along other challenges like ADHD, obsessive-compulsive disorder (OCD), and anxiety. While some kids see symptoms lessen as they age, others need long-term, individualized treatment plans to manage both the tics and associated psychiatric conditions. Tourette syndrome is diagnosed when an individual has at least two motor tics and one vocal tic for more than 12 months, with onset before age 18 [1]. These tics are sudden, repetitive, and involuntary—for example, blinking, throat clearing, or shoulder shrugging. A helpful diagnostic clue is that people with TS can often suppress their tics briefly, unlike those with habit cough or psychogenic cough [1]. Differentiating TS from other movement or psychiatric disorders is key, especially since tics can wax and wane in intensity. That fluctuation, combined with the ability to voluntarily hold back tics for short periods, helps set Tourette's apart from conditions like dystonia or chorea. Behavioral therapy is the foundation of TS treatment, and CBIT is the gold standard. This structured approach combines habit reversal training with relaxation techniques and functional intervention strategies. CBIT helps individuals recognize premonitory urges—the sensations that precede tics—and teaches them to respond with competing behaviors that prevent the tic. CBIT has been shown to be effective across different delivery formats. A 2024 review found it worked in both in-person and telehealth settings—even when ADHD or OCD were present [4]. In fact, recent studies show that tele-CBIT sessions are almost as effective as in-office visits [5], making it a convenient option for families with busy schedules or living far from specialists. Medications like clonidine and guanfacine are often used for kids with mild to moderate tics—especially when ADHD is also present. These medications work on the brain's norepinephrine pathways to reduce hyperactivity and impulsivity which in turn can reduce tic severity. Their appeal is their safety profile. Compared to antipsychotics, alpha-2 agonists are less likely to cause serious side effects, making them a good starting point for young patients [2] [3]. When behavioral therapy and alpha-agonists don't work, antipsychotic medications may be added. These drugs target dopamine pathways—known to be involved in tic generation—but come with trade-offs. Aripiprazole and risperidone are commonly prescribed because they are better tolerated than older drugs like haloperidol. Meanwhile pimozide, a dopamine receptor blocker, has shown better outcomes than haloperidol in clinical trials [1]. For individuals with focal tics—like persistent eye blinking or neck movements—botulinum toxin injections can provide targeted relief by weakening overactive muscles [6]. Despite their effectiveness, antipsychotics require close monitoring. Side effects like sedation, weight gain, and movement disorders (e.g., tardive dyskinesia) can emerge especially with long-term use. Clinicians must weigh the benefits of symptom relief against the risk of side effects and adjust treatment accordingly [3]. For the small percentage of individuals with treatment-refractory TS, Deep Brain Stimulation (DBS) may be considered. DBS involves surgically implanting electrodes into specific brain regions to modulate abnormal activity. While still relatively rare and not standard care, DBS has shown promising results in reducing severe tics in select patients [6]. Beyond medical interventions, holistic care is key. Support groups, patient education and school-based accommodations—like extended test times or breaks during class—can make a big difference in a child's social and academic success. TS isn't just about the tics—it's about the whole person. Comorbidities like OCD, ADHD, and anxiety often impact daily life more than the tics themselves. So treatment plans must be individualized and medication choices should consider these overlapping conditions [2]. Clinicians must also distinguish tics from other movement disorders. Features like premonitory urges, voluntary suppression and the episodic nature of tics can help differentiate TS from other hyperkinetic disorders [1]. Tourette syndrome may be lifelong but it doesn't have to be life defining. With the right combination of behavioral therapy, medication, support and education most people can manage their symptoms and live well. As research advances—especially in digital therapy delivery and neuromodulation—there's more hope for more personalized, accessible and effective treatments for people with TS. [1] Irwin, R. S., Glomb, W. B., & Chang, A. B. (2006). Habit cough, tic cough, and psychogenic cough in adult and pediatric populations: ACCP evidence-based clinical practice guidelines. Chest, 129(1 Suppl), 174S–179S. [2] Egolf, A., & Coffey, B. J. (2014). Current pharmacotherapeutic approaches for the treatment of Tourette syndrome. Drugs of today (Barcelona, Spain : 1998), 50(2), 159–179. [3] Whittington, C., Pennant, M., Kendall, T., Glazebrook, C., Trayner, P., Groom, M., Hedderly, T., Heyman, I., Jackson, G., Jackson, S., Murphy, T., Rickards, H., Robertson, M., Stern, J., & Hollis, C. (2016). Practitioner Review: Treatments for Tourette syndrome in children and young people - a systematic review. Journal of child psychology and psychiatry, and allied disciplines, 57(9), 988–1004. [4] Kohler, K., Rosen, N., & Piacentini, J. (2025). Description, Implementation, and Efficacy of the Comprehensive Behavioral Intervention for Tics as First-Line Treatment for Tourette and Other Tic Disorders. Journal of child and adolescent psychopharmacology, 35(3), 126–134. [5] Morand-Beaulieu, S., Szejko, N., Fletcher, J., & Pringsheim, T. (2024). Behavioural Therapy for tic disorders: a comprehensive review of the literature. Expert review of neurotherapeutics, 24(12), 1181–1191. [6] Billnitzer, A., & Jankovic, J. (2020). Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 17(4), 1681–1693.
